https://doi.org/10.48047/AFJBS.6.Si4.2024.35-61

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Mucus-Penetrating Nanoparticles: Overcoming Barriers in Mucosal Drug Delivery

Farhad F Mehta [1], Kandavalli Divya [2], Mansi sinha [3], Vema Kiran [4], Ramenani Hari Babu [5], Avinash Kumar Vivekanand Mishra [6], Preety Choudhary [7], Satyajit Panda [8]*

1. Assistant Professor, School of Pharmaceutical sciences, UTD RGPV University, Bhopal, Madhya Pradesh
2. Assistant professor, Deparment of Pharmaceutical Technology,Vijaya Institute Of Pharmaceutical Sciences For Women, Vijaya College Rd, Beside Samsung Godown, Enikepadu, Vijayawada, Andhra Pradesh- 521108
3. Assistant professor, IIMT college of pharmacy, knowledge park-3, Greater Noida, Uttar Pradesh- 201310)
4. Professor, MB School of Pharmaceutical Sciences, (erstwhile Sree Vidyanikethan College of Pharmacy), Mohan Babu University, Tirupati-517102
5. Professor, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati
6. Research Scholar, ISBR Business School, # 107, Near INFOSYS, Behind BSNL Telephone Exchange, Electronic City - Phase I, Bangalore – 560100
7. Associate Professor, Goel Institute of Pharmaceutical Sciences, Faizabad road, Lucknow-226010
8. Assistant Professor, Department of Pharmaceutics, Institute of Pharmacy and Technology, Salipur, Cuttack, Odisha- 754202

Corresponding Author: Dr. Satyajit Panda

Designation and Affiliation: Assistant Professor, Department of Pharmaceutics, Institute of Pharmacy and Technology, Salipur, Cuttack, Odisha- 754202

Email Id: satya.jcp@gmail.com

Article Info
Volume 6, Issue Si4, 2024
Received: 12 Apr 2024
Accepted: 02 May 2024
doi:10.48047/AFJBS.6.Si4.2024.35-61

Abstract

Mucosal drug delivery systems offer significant advantages in administering therapeutics directly to mucosal surfaces, enhancing local treatment efficacy while minimizing systemic side effects. However, the mucus layer, which protects these surfaces, poses a substantial barrier to effective drug delivery due to its viscous and adhesive properties that hinder the diffusion of conventional drug formulations. To address this challenge, the development of mucus-penetrating nanoparticles (MPNs) has emerged as a groundbreaking strategy. MPNs are engineered with specific characteristics, such as optimal size, surface charge, and hydrophilicity, enabling them to navigate through the mucus barrier efficiently. These nanoparticles can be modified with surface coatings, like polyethylene glycol (PEG), to reduce mucoadhesion and enhance their diffusivity. Key findings indicate that MPNs significantly improve the bioavailability and therapeutic outcomes of drugs delivered to mucosal surfaces, such as the respiratory, gastrointestinal, reproductive, ocular, and nasal tracts. Clinical studies have demonstrated the potential of MPNs in treating various conditions, including respiratory diseases, gastrointestinal disorders, sexually transmitted infections, and ocular diseases, by providing targeted and sustained drug release. The implications for future research are profound, as ongoing advancements in nanoparticle technology and personalized medicine promise to further enhance the efficiency and specificity of mucosal drug delivery systems. Additionally, addressing the challenges of safety, biocompatibility, regulatory compliance, and large-scale manufacturing will be crucial in translating these innovations from the laboratory to clinical practice. The continued exploration and optimization of MPNs are poised to revolutionize mucosal drug delivery, offering new hope for improved patient outcomes and expanded therapeutic possibilities.

Keywords: mucus-penetrating nanoparticles, drug delivery, mucosal barriers, nanoparticle design, personalized medicine, stimuli-responsive nanoparticles.

Introduction

Mucosal drug delivery systems have gained considerable attention over recent decades due to their potential to provide localized treatment at mucosal surfaces, which are the primary entry points for many pathogens and are involved in various physiological processes[1]. These surfaces include the respiratory tract, gastrointestinal tract, genitourinary tract, and ocular and nasal cavities[2]. Delivering drugs directly to these sites can enhance the therapeutic effect while minimizing systemic side effects, making mucosal drug delivery an attractive approach for treating a range of conditions.One of the major advantages of mucosal drug delivery is its ability to bypass the first-pass metabolism, which is a significant barrier for oral drug delivery[3,4]. This metabolism occurs in the liver, where a substantial portion of the drug can be metabolized before reaching systemic circulation, reducing its effectiveness. Additionally, mucosal delivery can facilitate a faster onset of action and improve patient compliance by

providing non-invasive and easily administrable formulations, such as sprays, drops, and suppositories[5].

Despite its advantages, mucosal drug delivery faces several challenges primarily due to the presence of the mucus layer, which acts as a protective barrier[6]. This layer, composed of glycoproteins called mucins, along with water, ions, and other molecules, is designed to trap and eliminate foreign particles, including pathogens and particulate matter[7]. The viscoelastic properties of mucus make it highly effective in protecting mucosal surfaces but simultaneously pose significant obstacles to drug delivery.One of the primary challenges is the mucus's rapid turnover rate[8]. The mucus layer is continuously secreted and shed, which can quickly remove drug formulations before they have the chance to penetrate the underlying epithelium. Furthermore, the mucus layer is highly adhesive, trapping particulate drug carriers and preventing their effective diffusion[9]. This mucoadhesion can drastically reduce the bioavailability of drugs, limiting their therapeutic potential.Additionally, the mucus layer varies in thickness, composition, and turnover rate across different mucosal surfaces and under different pathological conditions[10]. For instance, the mucus in the lungs is more viscoelastic compared to the relatively fluid mucus in the gastrointestinal tract. These variations necessitate tailored approaches to drug delivery that can address the specific characteristics of the mucus at each site[11].

To overcome the formidable barrier posed by mucus, researchers have developed mucus-penetrating nanoparticles (MPNs). These nanoparticles are specifically engineered to navigate through the mucus layer and deliver drugs effectively to the underlying tissues. The concept of MPNs hinges on optimizing several key properties, including particle size, surface charge, and hydrophilicity[12].The particle size of MPNs is critical, as particles that are too large may be trapped by the dense mesh of the mucus network. Typically, MPNs are designed to be small enough (usually in the range of 100-500 nanometers) to pass through the mucus pores. Surface charge also plays a crucial role; neutral or slightly negatively charged nanoparticles are less likely to interact electrostatically with the negatively charged mucins, reducing mucoadhesion[13]. Hydrophilicity is another important factor; hydrophilic surfaces can prevent protein adsorption and further reduce interactions with mucus.One of the most common strategies to achieve mucus penetration is the modification of nanoparticle surfaces with polyethylene glycol (PEG), a process known as PEGylation[14]. PEGylation imparts a "stealth" characteristic to nanoparticles, allowing them to diffuse through the mucus without being trapped. This modification has been shown to significantly enhance the transport of nanoparticles across the mucus barrier, leading to improved drug delivery outcomes[15].The development of MPNs has also involved the use of other materials and surface coatings that exhibit muco-inert properties. For instance, nanoparticles can be coated with surfactants or other hydrophilic polymers that enhance their ability to penetrate mucus[16]. Advances in nanotechnology have enabled the precise control over these properties, facilitating the creation of highly effective MPNs tailored for specific mucosal applications.This review aims to provide a comprehensive overview of the current state of research and development in the field of mucus-penetrating nanoparticles for mucosal drug delivery. It will explore the fundamental principles underlying the design and function of MPNs, examining how their physicochemical properties influence their ability to navigate the mucus barrier.

1. Mucosal Barriers and Their Implications for Drug Delivery

1.1. Structure and Function of Mucus

Mucus is a complex and dynamic viscoelastic gel that coats and protects the epithelial surfaces of the respiratory, gastrointestinal, genitourinary, ocular, and nasal tracts[17]. It is primarily composed of water (about 95%), glycoproteins known as mucins, lipids, proteins, salts, and various cells and cellular debris. Mucins, which are high molecular weight glycoproteins, are the primary structural components that give mucus its gel-like properties[18,5]. These mucins are extensively glycosylated, providing them with a high degree of hydration and resistance to proteolytic degradation.Mucins are produced by goblet cells in the epithelial layer and submucosal glands. The structure of mucins involves a protein backbone with dense regions of O-linked oligosaccharides, which are responsible for the formation of a gel network[19]. This network is capable of trapping and immobilizing particulates, including pathogens and environmental pollutants, due to its size-exclusion properties and adhesive nature.In addition to mucins, mucus contains various proteins such as enzymes, antibodies, and antimicrobial peptides that contribute to its protective functions. Lipids, although present in smaller quantities, play a role in maintaining the barrier properties of mucus by preventing dehydration and facilitating the formation of a hydrophobic layer[20,7,8].

Role of Mucus in Protecting Mucosal Surfaces

The primary role of mucus is to protect mucosal surfaces from mechanical damage, pathogens, and environmental toxins through several mechanisms[21]. Firstly, mucus acts as a physical barrier by trapping and immobilizing particles, bacteria, and viruses, thereby preventing them from reaching the underlying epithelial cells and causing infections or damage[22]. Secondly, its high water content maintains hydration of epithelial surfaces, essential for their proper function, and provides lubrication to reduce friction and prevent mechanical injury[23]. Thirdly, mucus contains immunoglobulins (especially IgA), lysozymes, lactoferrin, and antimicrobial peptides that neutralize pathogens, forming a critical part of the innate immune response[24,2]. Fourthly, while mucus blocks large molecules, it selectively permits the diffusion of nutrients, gases, and other essential small molecules necessary for cellular function. Lastly, mucus serves as a habitat for commensal microbiota, beneficial microorganisms that regulate microbial populations by outcompeting pathogens, thereby contributing to the maintenance of mucosal health[25].

1.2. Barriers to Drug Delivery

Physical and Chemical Barriers Presented by Mucus

The protective functions of mucus, crucial for maintaining mucosal health, also present substantial hurdles for effective drug delivery. These challenges stem from both the physical and chemical properties of mucus[26]. Firstly, its viscoelastic nature, formed by a network of mucin proteins, results in high viscosity and elasticity, impeding the penetration of drug particles. These particles can become ensnared in the mucin meshwork, hindering their movement through the mucus layer due to entanglement and adhesive interactions with mucins[27]. Secondly, mucins' extensive glycosylation leads to hydrophilic and potentially electrostatic interactions with drug molecules, causing mucoadhesion where drugs adhere to

the mucus surface rather than diffusing through it[28]. Thirdly, mucus undergoes continual production and shedding, with varying turnover rates across different mucosal surfaces. This rapid turnover mechanism can swiftly eliminate drug formulations before they reach their intended target cells, particularly evident in the respiratory tract where ciliary action expedites mucus clearance[29]. Fourthly, mucus composition and thickness vary significantly depending on anatomical location and pathological conditions, such as the thicker, more viscous mucus observed in cystic fibrosis patients' lungs, exacerbating the challenge of drug penetration[30]. Lastly, the mucus layer's chemical environment, characterized by a slightly acidic pH and containing enzymes and ions, poses additional hurdles by potentially degrading or inactivating drug molecules, especially susceptible are peptide and protein drugs vulnerable to enzymatic degradation by proteases and glycosidases[31].

Impact on Drug Absorption and Efficacy

The barriers posed by mucus significantly impact the absorption and efficacy of drugs targeted at mucosal surfaces. These effects manifest in several ways: firstly, drug particles trapped and adhered within the mucus layer reduce the amount reaching epithelial cells, necessitating higher doses that may pose toxicity risks[32]. Secondly, drugs requiring rapid action, like asthma rescue medications, face delays penetrating the mucus barrier, compromising their timely efficacy. Thirdly, varying mucus composition and thickness lead to inconsistent drug delivery, affecting therapeutic predictability and dosing precision[33]. Fourthly, enzymatic degradation within mucus, especially for peptides and proteins, reduces drug concentrations and efficacy, exacerbated by the acidic environment altering drug properties. Lastly, mucus interference hampers drugs' ability to target specific receptors on epithelial cells, undermining their precision and therapeutic effectiveness[34].

Strategies to Overcome Mucus Barriers

To overcome the challenges posed by mucus barriers in drug delivery, several innovative strategies have been developed. Mucus-Penetrating Nanoparticles (MPNs) are engineered with optimized particle size, surface charge, and hydrophilicity to effectively navigate through the mucus layer without being trapped or degraded, thereby enhancing drug transport to underlying tissues[35]. Mucoadhesive polymers offer another approach by enhancing drug retention at mucosal surfaces while balancing adhesion to prevent excessive sticking[31]. Co-delivery of enzyme inhibitors alongside drugs protects against enzymatic degradation within mucus, particularly beneficial for fragile peptide and protein drugs[36]. pH-sensitive drug delivery systems are designed to remain stable in the acidic mucus environment but release their cargo in response to pH changes near epithelial cells, ensuring optimal drug efficacy[2]. Surface modifications, such as PEGylation, alter the surface properties of drug particles to minimize interactions with mucus components and improve penetration. Additionally, surfactants can reduce the viscoelasticity of mucus, thereby facilitating easier drug diffusion through the mucosal barrier[12]. These strategies collectively aim to enhance drug bioavailability, ensure targeted delivery, and improve therapeutic outcomes in mucosal drug delivery applications[37,1].

2. Design and Development of Mucus-Penetrating Nanoparticles

The development of mucus-penetrating nanoparticles (MPNs) represents a significant advancement in the field of drug delivery, particularly for targeting mucosal surfaces. Effective MPNs are designed to navigate the complex and protective mucus layer, ensuring

that therapeutic agents reach the underlying epithelial cells[38].



Figure 1: Generalized Graphical Depiction of Mucus Layer Dynamics and Fate of Particle Types upon Topical Administration: Microparticles and Conventional Nanoparticles Adhere to the Outer Mucus Layer and are Cleared via Mucociliary Clearance; Mucus-Penetrating Particles (MPPs) Evade Adhesion in the Rapidly Cleared Outer Layer, Achieve Uniform Distribution, and Penetrate Towards the Membrane-Associated Layer.

2.1. Characteristics of Effective MPNs

Size, Surface Charge, and Hydrophilicity

The design of MPNs hinges on optimizing several key physicochemical properties, namely size, surface charge, and hydrophilicity. These characteristics significantly influence the ability of nanoparticles to penetrate mucus.

1. Size: The size of nanoparticles is crucial for mucus penetration. Mucus is composed of a network of mucin fibers with pore sizes typically ranging from 100 to 500 nanometers. To effectively penetrate this network, MPNs must be sufficiently small, generally around 200 nanometers or less. Larger particles are more likely to become entangled in the mucin mesh, hindering their movement and reducing their bioavailability[39].

2. Surface Charge: The surface charge of nanoparticles affects their interaction with the negatively charged mucin fibers. Positively charged particles tend to adhere strongly to mucus due to electrostatic interactions, which can trap them within the mucus layer. Neutral or slightly negatively charged nanoparticles are preferable as they reduce these electrostatic interactions, enhancing their ability to diffuse through the mucus[40].

3. Hydrophilicity: Hydrophilic surfaces can help nanoparticles navigate the mucus barrier by reducing interactions with mucin fibers. Hydrophilic nanoparticles are less likely to be adsorbed onto the mucin network, facilitating their movement through the mucus. This property is often achieved by coating the nanoparticles with hydrophilic polymers, such as polyethylene glycol (PEG)[41].

Importance of Particle Design in Mucus Penetration

The design of nanoparticles is integral to their function and effectiveness in drug delivery. Effective particle design ensures that MPNs can traverse the mucus layer and deliver their therapeutic payload to the target site.

1. Avoiding Mucus Adhesion: By carefully designing nanoparticles with the right size, surface charge, and hydrophilicity, researchers can minimize adhesion to mucus. This design consideration is essential for ensuring that MPNs can move freely through the mucus to reach the epithelial cells[42].

2. Controlled Release: The design of MPNs often includes mechanisms for controlled drug release. Once the nanoparticles reach the mucosal surface, they should release their payload in a controlled manner to ensure sustained therapeutic effects. This can be achieved through various techniques, such as pH-sensitive coatings or biodegradable polymers[43].

3. Targeting Capabilities: Advanced MPNs may also incorporate targeting ligands on their surface to enhance their specificity for certain cell types or tissues. This targeting can improve the efficacy of drug delivery and reduce side effects by ensuring that the therapeutic agents are delivered precisely where they are needed[44].

2.2. Strategies for Enhancing Mucus Penetration

To enhance the penetration of nanoparticles through mucus, several strategies have been developed, focusing on surface modifications and the use of muco-inert materials.

PEGylation and Other Surface Modifications

1. PEGylation: One of the most effective and widely used strategies for enhancing mucus penetration is the modification of nanoparticles with polyethylene glycol (PEG), a process known as PEGylation. PEGylation imparts a hydrophilic and neutral surface to the nanoparticles, which reduces their interactions with mucin fibers[45]. This "stealth" property allows PEGylated nanoparticles to diffuse through the mucus more freely. Additionally, PEGylation can increase the stability and circulation time of nanoparticles in the body, further enhancing their therapeutic potential[46].

2. Surface Coatings with Hydrophilic Polymers: Besides PEG, other hydrophilic polymers can be used to coat nanoparticles and improve mucus penetration. Polymers such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and polysaccharides like hyaluronic acid and chitosan derivatives can also reduce mucoadhesion and enhance diffusion through mucus[47].

3. Zwitterionic Coatings: Zwitterionic materials, which contain both positive and negative charges, can create a highly hydrophilic and non-fouling surface on nanoparticles. These

coatings can reduce protein adsorption and interactions with mucin fibers, facilitating mucus penetration[48].



Figure 2: (a) Schematic illustrating the mucoadhesive and mucus-penetrating strategy with developed nanoparticles. Mucoadhesive nanoparticles (b) are good at catching the surface of mucous membrane whereas the mucus-penetrating nanoparticles (c) transport more effectively through the mucus layer.

Use of Muco-Inert Materials

1. Nanoparticles with Low Mucoadhesion: Using materials that naturally exhibit low mucoadhesion is another strategy for enhancing mucus penetration. Materials such as polylactic-co-glycolic acid (PLGA) and certain lipids can be used to fabricate nanoparticles that are less likely to stick to the mucus[49].

2. Surfactants and Detergents: Incorporating surfactants and detergents into nanoparticle formulations can reduce the viscoelastic properties of mucus, making it less of a barrier. Surfactants can disrupt the mucin network and decrease the mucus's cohesive forces, allowing nanoparticles to move through more easily[50].

3. Bio-Inspired Designs: Drawing inspiration from natural mucus-penetrating entities, such as certain bacteria and viruses, researchers have designed nanoparticles that mimic these

organisms' surface properties. For example, nanoparticles with surface proteins or peptides that mimic those of mucus-penetrating pathogens can be engineered to enhance penetration[51].

2.3. Methods of Synthesis

The synthesis of MPNs involves various techniques that allow precise control over their size, surface properties, and drug loading capacity. These methods include both top-down and bottom-up approaches[52].

Common Techniques for Nanoparticle Preparation

1. Emulsion-Solvent Evaporation: This technique involves creating an emulsion of the drug and polymer solution in an aqueous phase, followed by solvent evaporation. The resulting nanoparticles can be optimized for size and surface properties. This method is widely used for producing polymeric nanoparticles, such as PLGA nanoparticles[53].

2. Nanoprecipitation: Nanoprecipitation involves the precipitation of nanoparticles from a polymer solution upon the addition of a non-solvent. This technique is simple and effective for producing nanoparticles with a narrow size distribution. It is particularly suitable for hydrophobic drugs[54].

3. Self-Assembly: Certain amphiphilic molecules can self-assemble into nanoparticles in an aqueous environment. Liposomes and micelles are examples of self-assembled nanoparticles that can encapsulate both hydrophobic and hydrophilic drugs. This method allows for the easy incorporation of targeting ligands and surface modifications[55].

4. Spray Drying: Spray drying involves the atomization of a drug-polymer solution into a hot drying chamber, resulting in the formation of nanoparticles. This method is suitable for scaling up the production of nanoparticles and can be used to encapsulate a wide range of drugs[56].

5. Electrospinning: Electrospinning is a technique used to produce nanofibers and nanoparticles by applying a high voltage to a polymer solution. The resulting fibers can be processed into nanoparticles with controlled size and morphology. This method is useful for creating nanoparticles with high surface area and controlled release properties[57].

Encapsulation Methods for Various Drugs

1. Hydrophobic Drugs: Hydrophobic drugs can be encapsulated within the hydrophobic core of nanoparticles using techniques such as nanoprecipitation and emulsion-solvent evaporation. These methods protect the drug from degradation and enhance its solubility and bioavailability[58,25].

2. Hydrophilic Drugs: Encapsulating hydrophilic drugs can be more challenging due to their tendency to leak from the nanoparticles. Techniques such as self-assembly into liposomes and micelles or using double emulsion methods can effectively encapsulate hydrophilic drugs. In the double emulsion technique, the hydrophilic drug is first emulsified in an organic phase, which is then emulsified again in an aqueous phase to form stable nanoparticles[14,7].

3. Proteins and Peptides: Encapsulating proteins and peptides requires gentle techniques to preserve their biological activity[13]. Methods such as coacervation, where a polymer and protein solution are mixed to form coacervates that are then hardened into nanoparticles, are effective. Encapsulation can also be achieved using self-assembly into liposomes or nanoparticles formed by ionic gelation[32].

4. Nucleic Acids: Delivering nucleic acids, such as DNA, RNA, and siRNA, involves encapsulating these molecules within nanoparticles to protect them from degradation and facilitate cellular uptake[22]. Techniques such as complexation with cationic polymers or lipids, followed by nanoparticle formation, are commonly used. These methods can produce nanoparticles that efficiently deliver nucleic acids to target cells[59].

Quality Control and Characterization

Ensuring the quality and consistency of MPNs involves rigorous characterization of their physicochemical properties. Key parameters to assess include:

1. Particle Size and Size Distribution: Techniques such as dynamic light scattering (DLS) and transmission electron microscopy (TEM) are used to measure particle size and size distribution. A narrow size distribution is essential for consistent mucus penetration and drug delivery[19].

2. Surface Charge (Zeta Potential): The surface charge of nanoparticles, measured by zeta potential analysis, provides insight into their stability and interaction with mucus. Neutral or slightly negative zeta potentials are preferable for mucus penetration[31].

3. Surface Morphology: Scanning electron microscopy (SEM) and TEM provide detailed images of nanoparticle morphology, revealing surface characteristics and structural integrity[44].

4. Drug Loading and Encapsulation Efficiency: High-performance liquid chromatography (HPLC) and other analytical techniques quantify the amount of drug loaded into nanoparticles and determine the encapsulation efficiency. This information is crucial for dosing and therapeutic efficacy[20].

5. Stability and Release Profiles: Stability studies assess the shelf life of nanoparticles, while in vitro release studies determine the drug release kinetics. These studies ensure that nanoparticles remain effective over time and release their payloads in a controlled

manner[39].

3. Mechanisms of Mucus Penetration

Effective drug delivery through mucosal surfaces requires a comprehensive understanding of the mechanisms by which nanoparticles (NPs) can penetrate the mucus barrier.

3.1. Diffusion through Mucus

Theoretical Models and Experimental Studies

Diffusion through mucus is a critical mechanism for nanoparticle transport. Theoretical models and experimental studies provide insights into how nanoparticles move through the mucus layer.

1. Theoretical Models: The diffusion of nanoparticles through mucus can be described by Fick's laws of diffusion, which quantify the relationship between the concentration gradient and the rate of particle movement. These models help predict the behavior of nanoparticles based on their size, surface properties, and the viscosity of the mucus[60].

2. Experimental Studies: Experimental techniques such as fluorescence recovery after photobleaching (FRAP), particle tracking microrheology, and multiple particle tracking (MPT) have been used to study nanoparticle diffusion in mucus[29,8]. FRAP involves photobleaching a region of fluorescently labeled mucus and measuring the time required for fluorescence recovery, which indicates the diffusion rate of nanoparticles. MPT involves tracking the motion of individual nanoparticles in real time to provide detailed information on their trajectories and diffusion coefficients[61].

Role of Particle Size and Surface Properties

The size and surface properties of nanoparticles play a crucial role in their ability to diffuse through mucus.

1. Particle Size: Smaller nanoparticles generally diffuse more readily through the mucus network due to their ability to navigate the pore sizes of the mucin mesh. Studies have shown that nanoparticles smaller than 200 nm can penetrate mucus more effectively than larger particles. However, extremely small nanoparticles (less than 50 nm) may also face challenges due to rapid clearance and potential for deeper penetration beyond the target site[62].

2. Surface Properties: Surface charge and hydrophilicity significantly impact the interaction of nanoparticles with mucus[18]. Neutral or slightly negative surface charges are preferable to minimize electrostatic interactions with the negatively charged mucins. Hydrophilic surfaces, achieved through modifications such as PEGylation, reduce mucoadhesion and enhance diffusivity. For instance, PEGylated nanoparticles demonstrate improved diffusion in

mucus due to their reduced tendency to bind to mucin fibers[63,6].

3.2. Overcoming Mucus Adhesion

Overcoming mucus adhesion is essential for enhancing the penetration of nanoparticles through the mucus barrier. This can be achieved by reducing mucoadhesiveness and enhancing diffusivity through various surface modifications.

Reducing Mucoadhesiveness through Surface Modifications

1. PEGylation: PEGylation involves attaching polyethylene glycol (PEG) chains to the surface of nanoparticles. PEGylation creates a hydrophilic and neutral surface that reduces the interaction with mucin fibers, thereby decreasing mucoadhesion[21]. This modification enhances the ability of nanoparticles to diffuse through the mucus. PEGylation has been widely studied and demonstrated to significantly improve the transport of nanoparticles in mucus[64].

2. Zwitterionic Coatings: Zwitterionic materials, which possess both positive and negative charges, provide a highly hydrophilic and non-fouling surface[37]. Zwitterionic coatings can minimize protein adsorption and interactions with mucin fibers, leading to improved mucus penetration. These coatings are particularly effective in reducing mucoadhesion while maintaining the stability and biocompatibility of nanoparticles[65].

3. Hydrophilic Polymers: Coating nanoparticles with hydrophilic polymers such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and hyaluronic acid can also reduce mucoadhesion. These polymers create a hydrated layer around the nanoparticles, preventing them from sticking to the mucus and facilitating their movement through the mucin network[66].

Enhancing Diffusivity with Hydrophilic Coatings

1. Hydrophilic Polymer Coatings: As mentioned, hydrophilic polymer coatings are effective in enhancing the diffusivity of nanoparticles. The hydrated layer formed by these polymers reduces friction and interactions with mucin fibers, allowing nanoparticles to move more freely through the mucus. For example, nanoparticles coated with hyaluronic acid have shown enhanced diffusion in the vaginal and nasal mucus[67].

2. Surface Functionalization: Surface functionalization with specific molecules or ligands that interact favorably with the mucus environment can further enhance diffusivity. For instance, functionalizing nanoparticles with mucin-mimetic glycopolymers can create a lubricated surface that mimics the natural components of mucus, reducing resistance to movement[68].

3. Bio-Inspired Strategies: Drawing inspiration from naturally occurring mucus-penetrating

entities, such as certain bacteria and viruses, researchers have developed nanoparticles that mimic these organisms' surface properties. For example, nanoparticles designed to mimic the surface proteins of mucus-penetrating viruses can exhibit enhanced diffusivity by leveraging similar mechanisms used by these pathogens to navigate through the mucus[69].

4. Applications of Mucus-Penetrating Nanoparticles

Mucus-penetrating nanoparticles (MPNs) have emerged as a revolutionary tool in drug delivery systems, offering significant advancements across various medical fields. Their ability to traverse the mucus barrier efficiently has opened new avenues for treating diseases affecting mucosal surfaces[70].

4.1. Respiratory Drug Delivery

MPNs have shown great promise in the field of respiratory drug delivery. Various case studies and clinical trials highlight their potential in treating respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

1. Asthma and COPD: Inhalable MPNs have been developed to deliver corticosteroids and bronchodilators directly to the lungs[5]. Clinical trials have demonstrated that these nanoparticles can improve drug deposition in the lower respiratory tract, leading to enhanced therapeutic outcomes and reduced systemic side effects. For instance, a study using PEGylated nanoparticles for the delivery of budesonide, a common asthma medication, showed improved lung retention and efficacy compared to traditional inhalers[71].

2. Cystic Fibrosis: MPNs have been employed to deliver antibiotics and gene therapy agents to the lungs of cystic fibrosis patients[22]. These nanoparticles can penetrate the thick mucus characteristic of cystic fibrosis, allowing for more effective treatment. Clinical trials with MPN-based antibiotic delivery systems have shown increased drug concentrations at the infection site and better clinical outcomes[72].

Benefits for Treating Respiratory Diseases

The benefits of using MPNs for respiratory drug delivery are manifold:

1. Enhanced Drug Penetration: MPNs can penetrate the thick mucus present in various respiratory diseases, ensuring that the drug reaches the target site more effectively[10].

2. Improved Drug Retention: By navigating through the mucus and reaching the epithelial surface, MPNs can provide sustained drug release, improving treatment efficacy and reducing dosing frequency[19].

3. Reduced Side Effects: Targeted delivery to the lungs minimizes systemic exposure and potential side effects, enhancing patient safety and compliance[73].

4.2. Gastrointestinal Drug Delivery

Targeted Delivery Systems for GI Disorders

The gastrointestinal (GI) tract presents unique challenges for drug delivery due to its harsh environment and protective mucus layer. MPNs have been developed to overcome these barriers and enhance the treatment of GI disorders[74].

1. Inflammatory Bowel Disease (IBD): MPNs designed to release anti-inflammatory drugs, such as corticosteroids and biologics, directly at the site of inflammation in conditions like Crohn's disease and ulcerative colitis have shown promising results. These nanoparticles can penetrate the mucus layer and deliver drugs precisely where they are needed, reducing systemic side effects[75].

2. Colon Cancer: MPNs have been explored for targeted delivery of chemotherapeutic agents to the colon. By encapsulating drugs in nanoparticles designed to release their payload in the presence of specific enzymes or pH conditions found in the colon, these systems can enhance the local concentration of the drug and improve therapeutic outcomes[76].

Enhanced Absorption of Oral Medications

1. Oral Bioavailability: MPNs can enhance the oral bioavailability of poorly soluble drugs by protecting them from degradation in the GI tract and facilitating their absorption through the mucus barrier. For example, nanoparticles encapsulating hydrophobic drugs have shown improved absorption and bioavailability compared to conventional formulations[77].

2. Controlled Release: MPNs can be engineered to provide controlled release of medications, improving the therapeutic profile and reducing the frequency of dosing. This is particularly beneficial for chronic conditions requiring long-term medication.

4.3. Reproductive Health and Genital Tract Applications

Drug Delivery for Sexually Transmitted Infections (STIs)

MPNs offer a novel approach for the prevention and treatment of sexually transmitted infections (STIs) by ensuring that therapeutic agents can effectively penetrate the genital tract mucus[78].

1. Antiviral and Antibacterial Agents: Nanoparticles designed to deliver antiviral drugs for HIV or antibacterial agents for chlamydia and gonorrhea can penetrate the mucus barrier and maintain higher drug concentrations at the site of infection. This targeted delivery enhances the effectiveness of the treatment and reduces the likelihood of resistance[79].

2. Microbicides: MPNs have been developed for the delivery of microbicides, which are substances that reduce the risk of STI transmission. These nanoparticles can provide

sustained release of the microbicide, offering prolonged protection[80].

Use in Fertility Treatments and Contraception

1. Fertility Treatments: MPNs can be used to deliver hormones and other drugs involved in fertility treatments directly to the reproductive tract, improving the efficacy of treatments such as in vitro fertilization (IVF).

2. Contraception: Nanoparticles have been explored for delivering contraceptive agents in a controlled manner. For example, MPNs can be used to release hormonal contraceptives slowly over time, providing a long-lasting contraceptive effect without the need for daily administration[81].

4.4. Ocular and Nasal Drug Delivery

Advantages in Treating Eye and Nasal Conditions

The ocular and nasal mucosal surfaces present unique challenges for drug delivery due to the presence of protective mucus and the need for precise targeting.

1. Ocular Drug Delivery: MPNs have been developed to improve the treatment of eye conditions such as glaucoma, age-related macular degeneration, and ocular infections. By penetrating the mucus layer and delivering drugs directly to the corneal or retinal tissues, these nanoparticles enhance drug bioavailability and therapeutic outcomes[14,19]. For instance, nanoparticles loaded with anti-glaucoma medications have shown improved intraocular pressure reduction and prolonged drug action compared to conventional eye drops[82].

2. Nasal Drug Delivery: The nasal route is advantageous for delivering drugs to the central nervous system and for treating nasal and sinus conditions[18]. MPNs can enhance the absorption of drugs through the nasal mucosa, providing rapid onset of action and improved bioavailability. Nasal delivery of MPNs loaded with analgesics, anti-inflammatory agents, and vaccines has shown significant benefits in terms of efficacy and patient compliance[83].

Innovations in Formulation and Administration

1. Formulation Techniques: Advances in formulation techniques have enabled the development of MPNs with optimized properties for ocular and nasal delivery. Techniques such as electrospinning and spray drying have been used to create nanoparticles with controlled release profiles and enhanced stability[84].

2. Administration Methods: Innovative administration methods, such as mucoadhesive gels and nasal sprays, have been developed to improve the delivery of MPNs. These methods ensure that the nanoparticles remain in contact with the mucosal surface for extended periods,

enhancing drug absorption and therapeutic efficacy[85].

5. Future Directions and Emerging Trends

The field of mucus-penetrating nanoparticles (MPNs) is rapidly evolving, with ongoing innovations poised to significantly enhance their effectiveness and expand their applications.

5.1. Innovations in Nanoparticle Technology

Next-Generation MPNs with Enhanced Functionalities

The development of next-generation MPNs focuses on incorporating advanced functionalities to improve drug delivery efficiency and therapeutic outcomes.

1. Stimuli-Responsive MPNs: These nanoparticles are designed to respond to specific stimuli such as pH, temperature, or enzymatic activity[12]. This responsiveness allows for targeted drug release at the desired site of action, minimizing side effects and enhancing therapeutic efficacy. For instance, MPNs that release their payload in response to the acidic environment of an inflamed tissue can provide targeted anti-inflammatory treatment[86].

2. Multifunctional MPNs: Incorporating multiple therapeutic agents or functionalities into a single nanoparticle can address complex diseases that require combination therapies[7]. Multifunctional MPNs can carry drugs, imaging agents, and targeting ligands simultaneously, enabling combined therapy and diagnostic (theranostic) capabilities. This approach is particularly beneficial for diseases like cancer, where simultaneous treatment and monitoring can significantly improve patient outcomes[87].

3. Biodegradable and Biocompatible MPNs: Developing MPNs from biodegradable and biocompatible materials ensures that they do not accumulate in the body and are safely metabolized or excreted. Advances in material science, such as the use of biodegradable polymers and lipids, contribute to the safety and efficacy of these nanoparticles[29,5].

Integration with Other Drug Delivery Systems

MPNs can be integrated with other drug delivery systems to create hybrid platforms that maximize therapeutic benefits:

1. Hydrogel-Based Systems: Combining MPNs with hydrogels can provide a sustained and controlled release of drugs. Hydrogels can protect the nanoparticles and facilitate their penetration through the mucus layer, while the MPNs ensure targeted delivery once they reach the mucosal surface[88].

2. Microneedle Arrays: Microneedle patches incorporating MPNs offer a minimally invasive method for delivering drugs through the skin. This approach can be particularly useful for

vaccines and other therapeutics that benefit from direct delivery to the bloodstream or lymphatic system[4,55].

3. Liposome and Vesicle Systems: MPNs can be incorporated into liposomes or other vesicular systems to enhance their stability and drug-loading capacity. These hybrid systems can improve the bioavailability of encapsulated drugs and provide more controlled release profiles[89].

5.2. Personalized Medicine and MPNs

Tailoring Nanoparticles to Individual Patient Needs

Personalized medicine aims to tailor treatments to individual patients based on their unique genetic, environmental, and lifestyle factors. MPNs can play a crucial role in this paradigm by offering customized drug delivery solutions:

1. Genetic Profiling: By utilizing genetic information, MPNs can be designed to deliver drugs that specifically target molecular pathways altered in a patient's disease. For example, MPNs can be loaded with siRNA or CRISPR-Cas9 components to modulate gene expression in a personalized manner[90].

2. Biomarker-Based Targeting: Identifying specific biomarkers associated with a patient's condition can guide the design of MPNs that target these markers. This targeted approach ensures that the therapeutic agents are delivered precisely where they are needed, enhancing efficacy and reducing side effects[24].

Advances in Precision Medicine

The integration of MPNs with precision medicine techniques can revolutionize healthcare by providing highly specific and effective treatments:

1. Tailored Drug Formulations: Advances in nanoparticle technology allow for the development of drug formulations that are specifically tailored to an individual's disease profile. This customization can lead to more effective treatments with fewer adverse effects[64].

2. Real-Time Monitoring and Adjustment: MPNs can be designed with embedded sensors or imaging agents that provide real-time feedback on drug delivery and therapeutic response. This information can be used to adjust treatment regimens dynamically, ensuring optimal therapeutic outcomes[91].

5.3. Research Gaps and Opportunities

Identifying Areas for Further Investigation

Despite significant advancements, several research gaps need to be addressed to fully realize the potential of MPNs:

1. Long-Term Safety and Toxicity: More studies are needed to understand the long-term safety and potential toxicity of MPNs, particularly concerning their accumulation and degradation in the body[45].

2. Mechanisms of Mucus Interaction: Further research is required to elucidate the detailed mechanisms by which MPNs interact with and penetrate mucus. This knowledge can guide the design of more efficient nanoparticles[54].

3. Clinical Translation: Bridging the gap between laboratory research and clinical application is critical. This involves scaling up the production of MPNs, ensuring their stability and efficacy in larger populations, and navigating regulatory challenges[92].

Potential for Interdisciplinary Research

Interdisciplinary collaboration can drive the development of innovative MPN technologies:

1. Material Science and Engineering: Collaborations with material scientists and engineers can lead to the discovery of new materials and fabrication techniques that enhance the properties of MPNs[39].

2. Biomedical Research: Partnerships with biomedical researchers can facilitate the integration of MPNs with biological systems, improving their functionality and therapeutic potential[55].

3. Clinical and Translational Medicine: Working closely with clinicians and translational researchers can ensure that MPN technologies are designed with practical applications in mind, speeding up the path from bench to bedside[93].

Conclusion

Mucus-penetrating nanoparticles (MPNs) represent a groundbreaking advancement in drug delivery technology, offering tailored solutions to overcome the formidable barriers presented by mucosal surfaces. The meticulous design of MPNs, focusing on size, surface charge, and hydrophilicity, enables them to navigate through the complex mucus layer with enhanced efficiency, thereby improving drug bioavailability and therapeutic efficacy. Applications across respiratory, gastrointestinal, reproductive health, ocular, and nasal domains highlight the versatility and potential of MPNs to revolutionize treatment paradigms for diverse diseases. Innovations such as stimuli-responsive and multifunctional MPNs, coupled with integration into hybrid delivery systems, promise further enhancements in targeted therapy and personalized medicine. The prospect of tailoring MPNs to individual patient needs through genetic profiling and biomarker-based targeting opens new avenues for precision

medicine, ensuring treatments are not only effective but also minimize side effects. However, continued research is crucial to address challenges such as long-term safety, scale-up for clinical translation, and interdisciplinary collaboration to optimize MPN design and application. With ongoing advancements and concerted efforts in these areas, MPNs are poised to play a pivotal role in the future of healthcare, offering hope for more effective, patient-friendly, and personalized therapeutic interventions that improve outcomes and quality of life for patients worldwide.

References

[1] B. Yavuz and U. B. Kompella, "Ocular drug delivery," in S. Whitcup and D. Azar, Eds., Pharmacologic Therapy of Ocular Disease, Handbook of Experimental Pharmacology, vol. 242. Cham: Springer International Publishing, 2017, pp. 57–93.

[2] K. Cholkar, S. P. Patel, A. D. Vadlapudi, and A. K. Mitra, "Novel strategies for anterior segment ocular drug delivery," J. Ocul. Pharmacol. Ther., vol. 29, pp. 106–123, 2013.

[3] H. H. Sigurdsson, J. Kirch, and C.-M. Lehr, "Mucus as a barrier to lipophilic drugs," Int. J. Pharm., vol. 453, pp. 56–64, 2013.

[4] S. K. Lai, Y.-Y. Wang, and J. Hanes, "Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues," Adv. Drug Deliv. Rev., vol. 61, pp. 158–171, 2009.

[5] L. M. Ensign, B. C. Tang, Y.-Y. Wang, et al., "Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus," Sci. Transl. Med., vol. 4, p. 138ra79, 2012.

[6] K. Maisel, L. Ensign, M. Reddy, R. Cone, and J. Hanes, "Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse," J. Control. Release., vol. 197, pp. 48–57, 2015.

[7] J. S. Suk, A. J. Kim, K. Trehan, et al., "Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier," J. Control. Release., vol. 178, pp. 8–17, 2014.

[8] C. Y. Dombu and D. Betbeder, "Airway delivery of peptides and proteins using nanoparticles," Biomaterials, vol. 34, pp. 516–525, 2013.

[9] X. Murgia, B. Loretz, O. Hartwig, M. Hittinger, and C. M. Lehr, "The role of mucus on drug transport and its potential to affect therapeutic outcomes," Adv. Drug Deliv. Rev., vol. 124, pp. 82–97, 2018.

[10] O. Lieleg and K. Ribbeck, "Biological hydrogels as selective diffusion barriers," Trends Cell Biol., vol. 21, pp. 543–551, 2011.

[11] S. S. Olmsted, J. L. Padgett, A. I. Yudin, K. J. Whaley, T. R. Moench, and R. A. Cone, "Diffusion of macromolecules and virus-like particles in human cervical mucus," Biophys. J., vol. 81, pp. 1930–1937, 2001.

[12] B. A. Nichols, M. L. Chiappino, and C. R. Dawson, "Demonstration of the mucous layer of the tear film by electron microscopy," Invest. Ophthalmol. Vis. Sci., vol. 26, pp. 464–473, 1985.

[13] J. I. Prydal, P. Artal, H. Woon, and F. W. Campbell, "Study of human precorneal tear film thickness and structure using laser interferometry," Invest. Ophthalmol. Vis. Sci., vol. 33, pp. 2006–2011, 1992.

[14] J. I. Prydal and F. W. Campbell, "Study of precorneal tear film thickness and structure by interferometry and confocal microscopy," Invest. Ophthalmol. Vis. Sci., vol. 33, pp. 1996–2005, 1992.

[15] K. Gipson and T. Inatomi, "Cellular origin of mucins of the ocular surface tear film," in D. A. Sullivan and D. Dartt, Eds., Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2, Advances in Experimental Medicine and Biology. Boston, MA: Springer, 1998, pp. 221–227.

[16] P. Argüeso, A. Tisdale, S. Spurr-Michaud, M. Sumiyoshi, and I. K. Gipson, "Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye," Invest. Ophthalmol. Vis. Sci., vol. 47, pp. 113–119, 2006.

[17] M. Sumiyoshi, J. Ricciuto, A. Tisdale, I. K. Gipson, F. Mantelli, and P. Argüeso, "Antiadhesive character of mucin O-glycans at the apical surface of corneal epithelial cells," Invest. Ophthalmol. Vis. Sci., vol. 49, pp. 197–203, 2008.

[18] T. D. Blalock, S. J. Spurr-Michaud, A. S. Tisdale, et al., "Functions of MUC16 in corneal epithelial cells," Invest. Ophthalmol. Vis. Sci., vol. 48, pp. 4509–4518, 2007.

[19] P. Argüeso, A. Guzman-Aranguez, F. Mantelli, Z. Cao, J. Ricciuto, and N. Panjwani, "Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier," J. Biol. Chem., vol. 284, pp. 23037–23045, 2009.

[20] R. Langer, H. Chen, and J. Hanes, "The nano state," Available at: https://theophthalmologist.com/business-profession/the-nano-state (last accessed May 19, 2020).

[21] T. Kim, K. Sall, E. J. Holland, R. K. Brazzell, S. Coultas, and P. K. Gupta, "Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery," Clin. Ophthalmol., vol. 13, pp. 69–86, 2019.

[22] Rubin, B.K., "Physiology of airway mucus clearance," Respir. Care, vol. 47, pp. 761-768, 2002.

[23] Corfield, A.P., Carroll, D., Myerscough, N., Probert, C.S., "Mucins in the gastrointestinal tract in health and disease," Front. Biosci., vol. 6, pp. D1321-D1357, 2001.

[24] Gipson, I.K., "Mucins of the human endocervix," Front. Biosci., vol. 6, pp. D1245-D1255, 2001.

[25] Thornton, D.J., Carlstedt, I., Howard, M., Devine, P.L., Price, M.R., Sheehan, J.K., "Respiratory mucins: identification of core proteins and glycoforms," Biochem. J., vol. 316, pt. 3, pp. 967-975, 1996.

[26] Van Klinken, B.J., Dekker, J., Buller, H.A., Einerhand, A.W., "Mucin gene structure and expression: protection vs. adhesion," Am. J. Physiol., vol. 269, pp. G613-G627, 1995.

[27] Slayter, H.S., Wold, J.K., Midtvedt, T., "Intestinal mucin of germ-free rats: biochemical and electron-microscopic characterization," Carbohydr. Res., vol. 222, pp. 1-9, 1991.

[28] Celli, J.P., Turner, B.S., Afdhal, N.H., Ewoldt, R.H., McKinley, G.H., Bansil, R., Erramilli, S., "Rheology of gastric mucin exhibits a pH-dependent sol-gel transition," Biomacromolecules, vol. 8, pp. 1580-1586, 2007.

[29] Hehar, S.S., Mason, J.D., Stephen, A.B., Washington, N., Jones, N.S., Jackson, S.J., Bush, D., "Twenty-four hour ambulatory nasal pH monitoring," Clin. Otolaryngol. Allied Sci., vol. 24, pp. 24-25, 1999.

[30] Jayaraman, S., Joo, N.S., Reitz, B., Wine, J.J., Verkman, A.S., "Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity," Proc. Natl. Acad. Sci. U. S. A., vol. 98, pp. 8119-8123, 2001.

[31] Jordan, N., Newton, J., Pearson, J., Allen, A., "A novel method for the visualization of the in situ mucus layer in rat and man," Clin. Sci., vol. 95, pp. 97-106, 1998.

[32] Kerss, S., Allen, A., Garner, A., "A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents," Clin. Sci., vol. 63, pp. 187-195, 1982.

[33] Matsuo, K., Ota, H., Akamatsu, T., Sugiyama, A., Katsuyama, T., "Histochemistry of the surface mucous gel layer of the human colon," Gut, vol. 40, pp. 782-789, 1997.

[34] Pullan, R.D., Thomas, G.A., Rhodes, M., Newcombe, R.G., Williams, G.T., Allen, A., Rhodes, J., "Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis," Gut, vol. 35, pp. 353-359, 1994.

[35] van der Waaij, L.A., Harmsen, H.J., Madjipour, M., Kroese, F.G., Zwiers, M., van Dullemen, H.M., de Boer, N.K., Welling, G.W., Jansen, P.L., "Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells," Inflamm. Bowel Dis., vol. 11, pp. 865-871, 2005.

[36] Brownlee, I.A., Havler, M.E., Dettmar, P.W., Allen, A., Pearson, J.P., "Colonic mucus: secretion and turnover in relation to dietary fibre intake," Proc. Nutr. Soc., vol. 62, pp. 245-249, 2003.

[37] Holly, F.J., Lemp, M.A., "Tear physiology and dry eyes," Surv. Ophthalmol., vol. 22, pp. 69-87, 1977.

[38] King-Smith, P.E., Fink, B.A., Hill, R.M., Koelling, K.W., Tiffany, J.M., "The thickness of the tear film," Curr. Eye Res., vol. 29, pp. 357-368, 2004.

[39] Prydal, J.I., Artal, P., Woon, H., Campbell, F.W., "Study of human precorneal tear film thickness and structure using laser interferometry," Invest. Ophthalmol. Vis. Sci., vol. 33, pp. 2006-2011, 1992.

[40] Mainardes, R.M., Urban, M.C., Cinto, P.O., Chaud, M.V., Evangelista, R.C., Gremiao, M.P., "Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery," Curr. Drug Deliv., vol. 3, pp. 275-285, 2006.

[41] Dharmendra Bhati *et al.*, “FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS,” *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.749.

[42] J. Mangala *et al.*, “NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE

COMPOUNDS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.553.

[43] Rohit Kumar Trivedi *et al.*, "REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.521.

[44] H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.457.

[45] shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1655.

[46] S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical applications," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1415.

[47] Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," NeuroQuantology, vol. 20, no. 11, pp. 1258, 2022.

[48] S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.

[49] V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.

[50] A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.

[51] B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of

green materials. Singapore: Springer Nature Singapore, 2022.

[52] Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.

[53] Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.

[54] Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.

[55] P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.

[56] P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.

[57] P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.

[58] P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.

[59] P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.

[60] P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.

[61] Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.

[62] T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.

[63] M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.

[64] A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.

[65] M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.

[66] M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.

[67] M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.

[68] Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.

[69] Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.

[70] V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.

[71] K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.

[72] K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.

[73] K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.

[74] K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.

[75] S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.

[76] S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary

and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.

[77] S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.

[78] S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.

[79] R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.

[80] P. Bhatt et al., "Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (Echinochloa frumentacea) Grains Starch," Stärke/Starch, May 2024, doi: https://doi.org/10.1002/star.202300285.

[81] Kumar et al., "Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study," Journal of bioactive and compatible polymers, May 2024, doi: https://doi.org/10.1177/08839115241249143.

[82] Yurewicz, E.C., Matsuura, F., Moghissi, K.S., "Structural studies of sialylated oligosaccharides of human midcycle cervical mucin," J. Biol. Chem., vol. 262, pp. 4733-4739, 1987.

[83] Allen, A., Flemstrom, G., Garner, A., Kivilaakso, E., "Gastroduodenal mucosal protection," Physiol. Rev., vol. 73, pp. 823-857, 1993.

[84] Carlstedt, I., Lindgren, H., Sheehan, J.K., Ulmsten, U., Wingerup, L., "Isolation and characterization of human cervical-mucus glycoproteins," Biochem. J., vol. 211, pp. 13-22, 1983.

[85] Chao, C.C.W., Butala, S.M., Herp, A., "Studies on the isolation and composition of human ocular mucin," Exp. Eye Res., vol. 47, pp. 185-196, 1988.

[86] Quraishi, M.S., Jones, N.S., Mason, J., "The rheology of nasal mucus: a review," Clin. Otolaryngol., vol. 23, pp. 403-413, 1998.

[87] Samet, J.M., Cheng, P.W., "The Role of Airway Mucus in Pulmonary Toxicology," Environ. Health Perspect., vol. 102, pp. 89-103, 1994.

[88] Chao, C.C.W., Vergnes, J.P., Brown, S.I., "Fractionation and partial characterization of macromolecular components from human ocular mucus," Exp. Eye Res., vol. 36, pp. 139-150, 1983.

[89] Engel, E., Guth, P.H., Nishizaki, Y., Kaunitz, J.D., "Barrier function of the gastric mucus gel," Am. J. Physiol. Gastrointest. Liver Physiol., vol. 269, pp. G994-G999, 1995.

[90] Lai, S.K., Wang, Y.Y., Wirtz, D., Hanes, J., "Microrheology and Macrorheology of Mucus: Implications for Drug and Gene Delivery to Mucosal Tissues," Adv. Drug Deliv. Rev., vol. 60, pp. 75-87, 2008.

[91] Wolf, D.P., Blasco, L., Khan, M.A., Litt, M., "Human cervical mucus. I. Rheologic characteristics," Fertil. Steril., vol. 28, pp. 41-46, 1977.